三种抗丙型肝炎病毒酶联免疫吸附测定法在各类肝病患者中的临床评估
Clinical evaluation of three anti-HCV ELISAs in patients with various liver diseases.
作者信息
Kawano S, Fujiyama S, Sato S, Tanaka M, Goto M, Taura Y, Sato T, Kawahara T, Mizuno K, Nonaka S
机构信息
Third Department of Internal Medicine, Kumamoto University Medical School, Japan.
出版信息
Dig Dis Sci. 1992 Aug;37(8):1268-74. doi: 10.1007/BF01296571.
We measured antibodies to hepatitis C virus (HCV) in 380 patients with various liver diseases by three enzyme-linked immunosorbent assays (ELISAs): HCV antibody ELISA test (C100), KCL-163 (KCL) corresponding to the nonstructural protein of HCV, and JCC based on the translation product of the presumptive HCV core gene. Of 233 cases of non-A, non-B (NANB) liver disease, 63.9% were anti-C100 positive, 69.1% were anti-KCL positive, and 79.8% were anti-JCC positive. Detection of serum HCV-RNA in 213 cases of chronic NANB liver disease revealed that the concordance was 80.3% for C100, 86.4% for KCL, 94.8% for JCC, and 95.3% for all three ELISAs. Overall, 85.4% of chronic NANB cases were considered to have type C disease with HCV infection. The most reliable assays for diagnosing chronic NANB liver disease as type C appeared to be the KCL and JCC ELISAs.
我们通过三种酶联免疫吸附测定法（ELISA）检测了380例患有各种肝脏疾病患者的丙型肝炎病毒（HCV）抗体：HCV抗体ELISA检测（C100）、对应HCV非结构蛋白的KCL - 163（KCL）以及基于推测的HCV核心基因翻译产物的JCC。在233例非甲非乙型（NANB）肝病病例中，63.9%的患者抗C100呈阳性，69.1%的患者抗KCL呈阳性，79.8%的患者抗JCC呈阳性。对213例慢性NANB肝病病例进行血清HCV - RNA检测发现，C100的一致性为80.3%，KCL为86.4%，JCC为94.8%，三种ELISA检测的总体一致性为95.3%。总体而言，85.4%的慢性NANB病例被认为是丙型疾病伴HCV感染。诊断慢性NANB肝病为丙型最可靠的检测方法似乎是KCL和JCC ELISA。
Zotero 插件